A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2004
12/28/2004	US6835710 Use as ANTITUMOR AGENTS for treating breast, ovarian, brain, or skin tumors
12/28/2004	US6835564 Human endothelin converting enzyme-like proteins and polynucleotides encoding the same
12/28/2004	US6835563 Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1
12/28/2004	US6835562 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
12/28/2004	US6835557 DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
12/28/2004	US6835555 Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
12/28/2004	US6835550 Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
12/28/2004	US6835548 Isoforms of mouse serotonin 5-HT2c receptor
12/28/2004	US6835546 Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
12/28/2004	US6835544 Methods of screening for compounds that bind to activin receptor
12/28/2004	US6835536 Therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, in the treatment of microorganism-caused infections, which infections may be systemic, such as a
12/28/2004	US6835385 For therapy of tylomas (calluses and fissures), helomas (corns), keratoses (papules)
12/28/2004	US6835382 Ii peptide therapeutics to enhance antigen presentation
12/28/2004	US6835381 Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor
12/28/2004	US6835380 Antibodies against rat pituitary tumor transforming gene carboxy-terminal (PTTG-C) peptides
12/28/2004	US6835378 Method and compositions for inhibiting thrombin-induced coagulation
12/28/2004	US6835372 Mixtures of di-(tri)peptides and drugs such as cyclosporin used as aerosols; drug delivery
12/28/2004	US6835370 Diagnosis and treatment of malignant neoplasms
12/28/2004	CA2120709C Enzyme-orthokeratology
12/28/2004	CA2117199C Method for the treatment of the complications and pathology of diabetes
12/28/2004	CA2072874C Polypeptides having human dopaminergic receptor activity, nucleic acids coding for said polypeptides and uses thereof for screening active substances on said polypeptides
12/28/2004	CA2054358C High acid nutritional formulations
12/27/2004	CA2451268A1 Alpha2delta ligands for the treatment of fibromyalgia and other disorders
12/26/2004	CA2430835A1 Methods for making and breaking prions (prpsc) produced from native prions (prpc), in vitro and from recombinant prion proteins
12/23/2004	WO2004111270A2 Differential gene expression in schizophrenia
12/23/2004	WO2004111242A1 FACTOR VII OR VIIa GLA DOMAIN VARIANTS
12/23/2004	WO2004111237A1 RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET-DERIVED ENDOTHELIAL CELL GROWTH FACTOR (ECGF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
12/23/2004	WO2004111234A1 Novel protein
12/23/2004	WO2004111226A1 Urokinase plasminogen activator derived octapeptide in the treatment of multiple sclerosis
12/23/2004	WO2004111218A2 Method for producing glucoamylases and their uses
12/23/2004	WO2004111215A1 Novel phosphorylated sequences of the phosphatase cdc25b, antibodies for said sequences and use thereof
12/23/2004	WO2004111192A2 Targeted delivery to legumain-expressing cells
12/23/2004	WO2004111090A2 Molecules for targeting and releasing therapeutic compounds, and the use thereof
12/23/2004	WO2004111089A2 Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
12/23/2004	WO2004111088A2 Angiogenic factor and inhibitors thereof
12/23/2004	WO2004111087A2 Chemokin-binding protein thap1, methods and use thereof
12/23/2004	WO2004111086A2 Peptide analogues comprising at least one type of aminoacyl aza-$g(b)3 and the use thereof, in particular for therapy
12/23/2004	WO2004111085A1 Angiogenic factor and its medical use
12/23/2004	WO2004111084A2 Peptides enhancing ceh activity or inhibiting acat activity, pharmaceutical compositions comprising these peptides and their use in the treatment of atherosclerosis
12/23/2004	WO2004111080A1 Epitopes of the cytomegalovirus pp65 protein
12/23/2004	WO2004111078A2 Compounds that modulate the glucagon response and uses thereof
12/23/2004	WO2004111077A1 Macrocyclic antagonists of the motilin receptor
12/23/2004	WO2004111076A1 Triamide derivative and process for producing the same
12/23/2004	WO2004111075A2 Alternative reading frame polypeptides for treatment
12/23/2004	WO2004111074A2 In vivo production of a clostridial neurotoxin light chain peptide
12/23/2004	WO2004110980A1 Sphingolipids' polyalkylamines conjugates
12/23/2004	WO2004110533A1 Needleless syringe having medical agent accommodated therein
12/23/2004	WO2004110499A1 Sphingolipids polyalkylamine conjugates for use in transfection
12/23/2004	WO2004110496A1 Sphingoid polyalkylamine conjugates for vaccination
12/23/2004	WO2004110490A2 Use of vegf inhibitors for tumor regression
12/23/2004	WO2004110489A1 MEDICINAL COMPOSITION FOR PREVENTING OR TREATING Th1 TYPE IMMUNOLOGICAL DISEASE
12/23/2004	WO2004110487A1 Treatment of t cell mediated diseases by inhibition of fgfr3
12/23/2004	WO2004110485A1 Materials and methods for improved vaccination
12/23/2004	WO2004110479A1 Hyaluronate lyase-containing agent for treating acute myocardial infarction or symptoms thereof and for the treatment of postinfarction myocarditis and myocardial ischaemia
12/23/2004	WO2004110478A1 Inhibitors of cell migration
12/23/2004	WO2004110477A1 Inhibitors of the leukocyte prommp-9/beta(2) integrin complex
12/23/2004	WO2004110476A1 Pharmaceutcal composition for treating or preventing disorders of blood-brain barrier
12/23/2004	WO2004110475A1 Connective tissue derived polypeptides
12/23/2004	WO2004110474A1 Pharmaceutical composition for inducing apoptosis comprising a fusion protein between bfl-1 and green fluorescent protein or a gene encoding same
12/23/2004	WO2004110473A1 Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
12/23/2004	WO2004110472A2 Fusion proteins
12/23/2004	WO2004110471A1 Preventive or remedy for disease associated with apoptosis
12/23/2004	WO2004110470A2 Use of collagen peptides to inhibit infection
12/23/2004	WO2004110469A2 Formulations comprising factor viia and a factor vii related polypeptide
12/23/2004	WO2004110457A1 Matrix metalloproteinases inhibitors for the stimulation and protection of bone marrow stem cells
12/23/2004	WO2004110432A1 Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
12/23/2004	WO2004110416A2 Use of a cx3c agonist for the treatment of pain and for promoting nerve regeneration
12/23/2004	WO2004110392A2 Compositions and methods for treating coronavirus infection and sars
12/23/2004	WO2004110390A2 Anti-cd74 immunoconjugates and methods
12/23/2004	WO2004110389A2 Sigma ligands for neuronal regeneration and functional recovery
12/23/2004	WO2004110388A2 Sigma ligands for neuronal regeneration and functional recovery
12/23/2004	WO2004110387A2 Sigma ligands for neuronal regeneration and functional recovery
12/23/2004	WO2004110373A2 Therapeutic vaccine compositions for the treatment of type 1 diabetes
12/23/2004	WO2004110371A2 Method for the treatment of malignancies
12/23/2004	WO2004110365A2 Liver related disease compositions and methods
12/23/2004	WO2004110362A2 Immunotherapeutics for biodefense
12/23/2004	WO2004110358A2 Polymeric conjugates for tissue activated drug delivery
12/23/2004	WO2004110356A2 Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
12/23/2004	WO2004110353A2 Novel immunomodulating peptide
12/23/2004	WO2004110341A2 Antimicrobial and anticancer lipopeptides
12/23/2004	WO2004110245A2 Combination therapy for cancer treatment
12/23/2004	WO2004110174A1 Composition and foods for lowering glycemic index
12/23/2004	WO2004096181A3 Solid dosage form comprising desmopressin
12/23/2004	WO2004096125A3 Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
12/23/2004	WO2004094673A8 Methods for monitoring drug activities in vivo
12/23/2004	WO2004094465A8 Synthetic molecules that mimic chemokines
12/23/2004	WO2004090151A3 Method for extracting collagen comprising microbial fermentation
12/23/2004	WO2004089354A3 Peptides and derivatives thereof as inhibitors of oxidative-induced degradation phenomena and compositions containing them
12/23/2004	WO2004087864A3 Amended recombinant cells (arcs) for the production and delivery of antiviral agents, adjuvants and vaccine accelerants
12/23/2004	WO2004084943A8 Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
12/23/2004	WO2004082459A3 Methods of administering a material into a patient for dermal enhancement
12/23/2004	WO2004080416A3 Animal model simulating neurologic disease
12/23/2004	WO2004072269A3 Bex4 nucleic acids, polypeptides, and method of using
12/23/2004	WO2004072263A3 Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
12/23/2004	WO2004071429A3 Lung inflammation treatment
12/23/2004	WO2004056317A3 Compositions for the treatment and prevention of nephropathy
12/23/2004	WO2004045563A3 Method of treatment of myocardial infarction
12/23/2004	WO2004045499A3 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
12/23/2004	WO2004036186A3 Microencapsulation and sustained release of biologically active polypeptides
12/23/2004	WO2004024182A3 Method for isolating hepatitis c virus peptides

1 ... 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 ... 3163